Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

114 trials

NCT06995872
Recruiting
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
Phase 1 · United States · 1 site
Registry update: 21 Oct 2026
2025-521497-34-00
Recruiting
Long-term follow-up of patients treated with GD2IL18CART
Phase 1 · Germany · 4 sites
Registry update: 23 Sept 2026
NCT06942039
Recruiting
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
Early phase 1 · Canada · 13 sites
Registry update: 2 Nov 2026
NCT07087002
Recruiting
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
Phase 1 · United States · 1 site
Registry update: 9 Oct 2026
NCT06479811
Recruiting
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Phase 1 · United States · 1 site
Registry update: 6 Oct 2026
NCT07067346
Recruiting
Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma
Early phase 1 · China · 1 site
Registry update: 29 Jul 2025
NCT07027748
Recruiting
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
Phase 1 · United States · 2 sites
Registry update: 14 Jul 2026
2023-504246-64-02
Recruiting
A phase I/II trial of ABTL0812 in children with relapsed/refractory neuroblastoma and other solid tumours
Phase 1/2 · Spain · 7 sites
Registry update: 30 Mar 2026
NCT06933394
Recruiting
Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma
Phase 2 · China · 1 site
Registry update: 18 Apr 2025
NCT06831552
Recruiting
Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
Not applicable · United States · 6 sites
Registry update: 10 Feb 2026
NCT07100704
Recruiting
Recurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of Nivolumab
Phase 2 · Japan · 2 sites
Registry update: 3 Aug 2025
NCT06721689
Recruiting
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Phase 1/2 · United States · 7 sites
Registry update: 6 Oct 2026
2024-520436-15-00
Recruiting
Phase I/II study of anti-GD2 Chimeric Antigen Receptor-Expressing T cells in pediatric patients affected by High Risk and/or relapsed/refractory Neuroblastoma and other relapsed/refractory GD2+ tumors
Phase 1/2 · Italy · 1 site
Registry update: 17 Feb 2025
NCT06852807
Recruiting
18F-mFBG PET Imaging in the Evaluation of Neuroblastoma
Not applicable · China · 1 site
Registry update: 8 Aug 2025
NCT07141862
Recruiting
Fertility Preservation in Children With Solid Tumors: Detection of Residual Disease by a Sensitive Method
Not applicable · France · 1 site
Registry update: 3 Sept 2025
NCT06803875
Recruiting
Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
Phase 1/2 · United States · 2 sites
Registry update: 26 Dec 2025
NCT06485947
Recruiting
Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma
Phase 1 · Austria, Germany, Spain, France, Italy, Netherlands, Poland · 14 sites
Registry update: 8 Jul 2025
NCT06674811
Recruiting
Biomarkers of Resiliency In Childhood Cancer Surgery
Not applicable · United States · 1 site
Registry update: 14 Sept 2026
NCT06751134
Recruiting
Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma
Phase 1 · China · 2 sites
Registry update: 7 Feb 2025
NCT07195500
Recruiting
Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma
Not applicable · China · 1 site
Registry update: 26 Sept 2025

Ordered by registry start date. Freshness and sponsorship never change the order.